Furthermore, we discuss the use of Immune Checkpoint Blockade (ICB) in HNSCC treatment, the ongoing clinical trials testing several combinations of immune checkpoint inhibitors with other therapeutic approaches, and novel predictive biomarkers of response to anti-PD-1/PD-L1 therapy. Here, CD274 is linked to head and neck squamous cell carcinoma.